[ad_1]
Certara (Nasdaq: CERT), a global leader in the field of biological simulation, announced today that Mubadala Investment Corporation (Mubadala) has invested approximately US$250 million in Certara. This investment is in line with Mubadala’s strategy of solving unmet clinical needs and improving cost efficiency through innovation.
Certain existing institutional shareholders of Mubadala and Certara, including shareholders related to EQT, have reached an agreement under which Mubadala’s affiliates will purchase a total of 9,615,384 shares from shareholders in a private transaction at a price of $26 per share. The transaction is scheduled to be completed on August 2, 2021. After the transaction is completed, EQT will remain an important shareholder of the company.
Certara CEO William F. Feehery said: “We are very pleased to welcome Mubadala to make a major new investment. Mubadala is a sovereign investor with deep expertise in the life sciences and focuses on creating lasting Value.” “As a newly listed public company, Mubadala is excited about Certara’s performance and recognition as a global leader in the field of bio-simulation, especially as we execute the next phase of growth.”
Camilla Languille, director of life sciences at Mubadala, said: “Biosimulation is changing traditional drug development through computational methods, saving time and costs throughout the biopharmaceutical development process. We are proud to invest in Certara, whose market-leading software is accelerating development and improving patients. New medicine for life.”
Eric Liu, Co-Head of EQT’s Global Healthcare Team, added: “We welcome Mubadala as Certara’s new shareholder. EQT is still an important investor in Certara and we look forward to continuing to support the management team to accelerate delivery to patients through the use of biological simulations. Efforts to provide medicine.”
[ad_2]
Source link